keyword
https://read.qxmd.com/read/38652803/apparent-mineralocorticoid-excess-in-israel-a-case-series-and-literature-review
#1
JOURNAL ARTICLE
Asaf Lebel, Efrat Ben Shalom, Rozan Mokatern, Raphael Halevy, Yoav Zehavi, Daniela Magen
BACKGROUND AND OBJECTIVE: Apparent mineralocorticoid excess (AME) syndrome is an ultra-rare autosomal-recessive tubulopathy, caused by mutations in HSD11B2, leading to excessive activation of the kidney mineralocorticoid receptor, and characterized by early-onset low-renin hypertension, hypokalemia, and risk of chronic kidney disease (CKD). To date, most reports included few patients, and none described patients from Israel. We aimed to describe AME patients from Israel and to review the relevant literature...
April 23, 2024: European Journal of Endocrinology
https://read.qxmd.com/read/38652434/short-and-long-term-post-nephrectomy-outcomes-for-retroperitoneal-liposarcoma-from-a-high-volume-sarcoma-center-a-propensity-score-matching-analysis
#2
JOURNAL ARTICLE
Guoqiang Xue, Zhen Wang, Bonan Liu, Chengpeng Li, Ang Lv, Xiuyun Tian, Jianhui Wu, Hui Qiu, Chunyi Hao
BACKGROUND: Multivisceral en bloc resection with the ipsilateral kidney is commonly performed in patients with retroperitoneal liposarcoma (RLPS). We evaluated the effect of nephrectomy on short- and long-term outcomes in patients with RLPS. METHODS: Data from a prospectively maintained database of the Peking University Cancer Hospital Sarcoma Center between April 2011 and August 2022 were analyzed. We classified the RLPS patients who underwent surgery into nephrectomy group (NP) and non-nephrectomy group (non-NP)...
April 23, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38651148/a-study-of-high-dose-furmonertinib-in-egfr-exon-20-insertion-mutation-positive-advanced-non-small-cell-lung-cancer
#3
JOURNAL ARTICLE
Song Hu, Hao Ming, Qian He, Ming Ding, Hao Ding, Chong Li
BACKGROUND: The epidermal growth factor receptor (EGFR) ex20ins mutation, as a rare subtype of mutation, has gradually attracted attention. Its heterogeneity is high, its prognosis is extremely poor, and the efficacy of existing traditional treatment plans is limited. In this study, we aimed to evaluate efficacy of high dose furmonertinib as a first-line treatment for EGFR ex20ins-positive NSCLC. METHODS: This is a retrospective, multi-center, non-interventional study...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38650801/the-association-of-the-epidermal-growth-factor-receptor-egfr-immunoexpression-with-prognostic-parameters-in-adenocarcinoma-patients-receiving-neoadjuvant-treatment
#4
JOURNAL ARTICLE
Derya Demir, Murtaza Parvizi, Burcin Pehlivanoglu, Erhan Ergin, Semin Ayhan, Basak Doganavsargil
The epidermal growth factor receptor (EGFR) expression is considered to play an essential role in the pathogenesis of colorectal adenocarcinoma. This study assessed the expression and predictive/prognostic value of EGFR expression in pre-op biopsy and post-op resection specimens in patients receiving neoadjuvant radiotherapy/neoadjuvant chemoradiotherapy (NRT/NCRT). Thirty-four consecutive patients were included in this study. The association between the prognostic features and EGFR immunohistochemical expression was analyzed in pre- (n=34) and post-treatment (n=22) tissue samples in cases with available tissue blocks...
March 2024: Curēus
https://read.qxmd.com/read/38650758/validation-of-the-klinrisk-chronic-kidney-disease-progression-model-in-the-fidelity-population
#5
JOURNAL ARTICLE
Navdeep Tangri, Thomas Ferguson, Silvia J Leon, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis M Ruilope, Alfredo E Farjat, Youssef M K Farag, Patrick Schloemer, Robert Lawatscheck, Katja Rohwedder, George L Bakris
BACKGROUND: Chronic kidney disease (CKD) affects >800 million individuals worldwide and is often underrecognized. Early detection, identification and treatment can delay disease progression. Klinrisk is a proprietary CKD progression risk prediction model based on common laboratory data to predict CKD progression. We aimed to externally validate the Klinrisk model for prediction of CKD progression in FIDELITY (a prespecified pooled analysis of two finerenone phase III trials in patients with CKD and type 2 diabetes)...
April 2024: Clinical Kidney Journal
https://read.qxmd.com/read/38650643/association-of-time-averaged-serum-uric-acid-level-with-clinicopathological-information-and-long-term-outcomes-in-patients-with-iga-nephropathy
#6
JOURNAL ARTICLE
Mengjie Weng, Binbin Fu, Yongjie Zhuo, Jiaqun Lin, Zhenhuan Zou, Yi Chen, Jiong Cui, Guifen Li, Caiming Chen, Yanfang Xu, Dewen Jiang, Jianxin Wan
OBJECTIVE: Whether serum uric acid (SUA) at baseline could been identiûed as a risk factor for progression in IgA nephropathy (IgAN) patients remains unclear, therefore, long- term SUA control levels must be monitored. We aimed to investigate the relevant factors affecting time-averaged SUA (TA-SUA) and to assess the prognostic value of TA-SUA in IgAN. METHODS: This retrospective study included 152 patients with IgAN. The relationships between TA-SUA and clinicopathological features and renal outcomes (defined as the doubling of the baseline serum creatinine level or end-stage renal disease) were analyzed in groups divided by quartiles of TA-SUA levels, the presence of hyperuricemia, and sex...
2024: PeerJ
https://read.qxmd.com/read/38650538/a-case-report-of-loss-of-thyroid-transcription-factor-1-expression-in-lung-adenocarcinoma-ebus-fna
#7
JOURNAL ARTICLE
Hitesh Mathew, Ros Bartle-Jones
We present a case report of a 76-year-old male with a histologically confirmed KRAS mutated, thyroid transcription factor 1 (TTF1) positive, grade 1, mucinous adenocarcinoma with cytologically difficult to interpret lymph node metastasis showing loss of TTF1 expression and overlapping features with goblet cell hyperplasia. The case highlights the importance of molecular testing in aiding diagnosis and guiding treatment of non-small cell lung carcinomas (NSCLC).
April 23, 2024: Diagnostic Cytopathology
https://read.qxmd.com/read/38650175/kinase-activities-in-pancreatic-ductal-adenocarcinoma-with-prognostic-and-therapeutic-avenues
#8
JOURNAL ARTICLE
Andrea Vallés-Martí, Richard R de Goeij-de Haas, Alex A Henneman, Sander R Piersma, Thang V Pham, Jaco C Knol, Joanne Verheij, Frederike Dijk, Hans Halfwerk, Elisa Giovannetti, Connie R Jiménez, Maarten F Bijlsma
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited number of known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics provides a direct read-out of aberrant signaling and the resultant clinically relevant phenotype. Mass spectrometry (MS)-based proteomics and phosphoproteomics were applied to 42 PDAC tumors. Data encompassed over 19 936 phosphoserine or phosphothreonine (pS/T; in 5412 phosphoproteins) and 1208 phosphotyrosine (pY; in 501 phosphoproteins) sites and a total of 3756 proteins...
April 22, 2024: Molecular Oncology
https://read.qxmd.com/read/38650147/development-of-a-novel-six-dna-damage-response-related-prognostic-signature-in-osteosarcoma
#9
JOURNAL ARTICLE
Tianyang Li, Zhenzhou Tang, Sucheng Li, Minhua Lu
DNA damage response (DDR) plays a vital role in the development of cancer. Nevertheless, in osteosarcoma, the potential of DDR-related genes (DDRGs) remains unclear. Thus, the current research is intended to investigate the mechanisms of DDRGs in the development of osteosarcoma and to explore potential DDR-related biomarkers in forecasting the prognosis of osteosarcoma patients. The osteosarcoma genomic data from TCGA, GEO and cBioPortal databases were utilized for screening and identification of differentially expressed DDRGs (DEDDRGs)...
March 31, 2024: Cellular and Molecular Biology
https://read.qxmd.com/read/38650005/heterodimerization-of-t-cell-engaging-bispecific-antibodies-to-enhance-specificity-against-pancreatic-ductal-adenocarcinoma
#10
JOURNAL ARTICLE
Alan W Long, Hong Xu, Brian H Santich, Hongfen Guo, Sayed Shahabuddin Hoseini, Elisa de Stanchina, Nai-Kong V Cheung
BACKGROUND: EGFR and/or HER2 expression in pancreatic cancers is correlated with poor prognoses. We generated homodimeric (EGFRxEGFR or HER2xHER2) and heterodimeric (EGFRxHER2) T cell-engaging bispecific antibodies (T-BsAbs) to direct polyclonal T cells to these antigens on pancreatic tumors. METHODS: EGFR and HER2 T-BsAbs were constructed using the 2 + 2 IgG-[L]-scFv T-BsAbs format bearing two anti-CD3 scFvs attached to the light chains of an IgG to engage T cells while retaining bivalent binding to tumor antigens with both Fab arms...
April 23, 2024: Journal of Hematology & Oncology
https://read.qxmd.com/read/38649770/dexrazoxane-inhibits-the-growth-of-esophageal-squamous-cell-carcinoma-by-attenuating-sdcbp-mda-9-syntenin-mediated-egfr-pi3k-akt-pathway-activation
#11
JOURNAL ARTICLE
Ruijuan Du, Nan Xiao, Li Han, KeLei Guo, Kai Li, Zhiguo Chen, Hui Zhang, Zijun Zhou, Yunlong Huang, Xulin Zhao, Hua Bian
Syndecan-binding protein (SDCBP) was reported to stimulate the advancement of esophageal squamous cell carcinoma (ESCC) and could potentially be a target for ESCC treatment. There is a growing corpus of research on the anti-tumor effects of iron chelators; however, very few studies have addressed the involvement of dexrazoxane in cancer. In this study, structure-based virtual screening was employed to select drugs targeting SDCBP from the Food and Drug Administration (FDA)-approved drug databases. The sepharose 4B beads pull-down assay revealed that dexrazoxane targeted SDCBP by interacting with its PDZ1 domain...
April 22, 2024: Scientific Reports
https://read.qxmd.com/read/38649732/discovery-of-gefitinib-1-2-3-triazole-derivatives-against-lung-cancer-via-inducing-apoptosis-and-inhibiting-the-colony-formation
#12
JOURNAL ARTICLE
En Gao, Ya Wang, Gao-Lu Fan, Guiqing Xu, Zi-Yuan Wu, Zi-Jun Liu, Jian-Cheng Liu, Long-Fei Mao, Xixi Hou, Shouhu Li
A series of 20 novel gefitinib derivatives incorporating the 1,2,3-triazole moiety were designed and synthesized. The synthesized compounds were evaluated for their potential anticancer activity against EGFR wild-type human non-small cell lung cancer cells (NCI-H1299, A549) and human lung adenocarcinoma cells (NCI-H1437) as non-small cell lung cancer. In comparison to gefitinib, Initial biological assessments revealed that several compounds exhibited potent anti-proliferative activity against these cancer cell lines...
April 22, 2024: Scientific Reports
https://read.qxmd.com/read/38649154/a-systematic-review-of-cardiac-surgery-clinical-prediction-models-that-include-intra-operative-variables
#13
REVIEW
Ceri Jones, Marcus Taylor, Matthew Sperrin, Stuart W Grant
BACKGROUND: Most cardiac surgery clinical prediction models (CPMs) are developed using pre-operative variables to predict post-operative outcomes. Some CPMs are developed with intra-operative variables, but none are widely used. The objective of this systematic review was to identify CPMs with intra-operative variables that predict short-term outcomes following adult cardiac surgery. METHODS: Ovid MEDLINE and EMBASE databases were searched from inception to December 2022, for studies developing a CPM with at least one intra-operative variable...
April 22, 2024: Perfusion
https://read.qxmd.com/read/38649102/carotid-endarterectomy-and-transcarotid-artery-revascularization-can-be-performed-with-acceptable-morbidity-and-mortality-in-patients-with-chronic-kidney-disease
#14
JOURNAL ARTICLE
Norma Elizaga, Rahul Ghosh, Nallely Saldana-Ruiz, Marc Schermerhorn, Peter Soden, Kirsten Dansey, Sara L Zettervall
INTRODUCTION: Patients with chronic kidney disease (CKD) are considered a high-risk population, and the optimal approach to the treatment of carotid disease remains unclear. Thus, we compared outcomes following carotid revascularization for patients with CKD by operative approach of carotid endarterectomy (CEA), transfemoral carotid artery stenting (TFCAS), and transcarotid arterial revascularization (TCAR). METHODS: The Vascular Quality Initiative was analyzed for patients undergoing carotid revascularizations (CEA, TFCAS and TCAR) from 2016-2021...
April 20, 2024: Journal of Vascular Surgery
https://read.qxmd.com/read/38648778/risk-of-chronic-kidney-disease-in-260-patients-with-lupus-nephritis-analysis-of-a-nationwide-multicentre-cohort-with-up-to-35-years-of-follow-up
#15
JOURNAL ARTICLE
Filipa Farinha, Sofia Barreira, Maura Couto, Margarida Cunha, Diogo Fonseca, Raquel Freitas, Luís Inês, Mariana Luís, Carla Macieira, Ana R Prata, Joana Rodrigues, Bernardo Santos, Rita Torres, Ruth J Pepper, Anisur Rahman, Maria J Santos
OBJECTIVES: To compare proliferative (PLN) and membranous (MLN) lupus nephritis (LN) regarding clinical and laboratory presentation and long-term outcomes; To investigate predictors of progression to chronic kidney disease (CKD). METHODS: Multicentre observational study, with retrospective analysis of a prospective cohort, using data from the Rheumatic Diseases Portuguese Registry-Reuma.pt. Patients with biopsy-proven PLN, MLN and mixed LN were included. Cox regression survival analysis was used to investigate predictors of CKD...
April 22, 2024: Rheumatology
https://read.qxmd.com/read/38648768/human-blood-serum-counteracts-egfr-her2-targeted-drug-lapatinib-impact-on-squamous-carcinoma-sk-br-3-cell-growth-and-gene-expression
#16
JOURNAL ARTICLE
Nina Shaban, Mikhail Raevskiy, Galina Zakharova, Victoria Shipunova, Sergey Deyev, Maria Suntsova, Maksim Sorokin, Anton Buzdin, Dmitri Kamashev
Lapatinib is a targeted therapeutic inhibiting HER2 and EGFR proteins. It is used for the therapy of HER2-positive breast cancer, although not all the patients respond to it. Using human blood serum samples from 14 female donors (separately taken or combined), we found that human blood serum dramatically abolishes the lapatinib-mediated inhibition of growth of the human breast squamous carcinoma SK-BR-3 cell line. This antagonism between lapatinib and human serum was associated with cancelation of the drug induced G1/S cell cycle transition arrest...
March 2024: Biochemistry. Biokhimii︠a︡
https://read.qxmd.com/read/38648537/molecular-docking-mmgbsa-and-admet-studies-of-phytoconstituents-of-ocimum-gratissimum-on-multiple-breast-cancer-targets
#17
JOURNAL ARTICLE
Basiru Olaitan Ajiboye, Toluwase Hezekiah Fatoki, Precious Ayorinde Akinnusi, Olawale Rasaq Ajuwon, Babatunji Emmanuel Oyinloye, Temitope Olawale Jeje, Olutunmise Victoria Owolabi, Oluwatosin O Ogedengbe, Claudia Genovese
O. gratissimum is one of the most common medicinal plants in every community in Nigeria. This plant has been presumed to be useful in the management of diseases including breast cancer, which is one the commonest cancers affecting women globally. Hence, this study aimed to computationally investigate the phytochemicals present in O. gratissimum by elucidate their binding dynamics against five selected molecular targets of breast cancer and predict their pharmacokinetics properties. Molecular docking, MMGBSA calculation and ADMET prediction were used...
April 22, 2024: Natural Product Research
https://read.qxmd.com/read/38647650/non-adherence-to-cardiometabolic-medication-as-assessed-by-lc-ms-ms-in-urine-and-its-association-with-kidney-and-cardiovascular-outcomes-in-type-2-diabetes-mellitus
#18
JOURNAL ARTICLE
Sara Denicolò, Vera Reinstadler, Felix Keller, Stefanie Thöni, Susanne Eder, Hiddo J L Heerspink, László Rosivall, Andrzej Wiecek, Patrick B Mark, Paul Perco, Johannes Leierer, Andreas Kronbichler, Herbert Oberacher, Gert Mayer
AIMS/HYPOTHESIS: Non-adherence to medication is a frequent barrier in the treatment of patients with type 2 diabetes mellitus, potentially limiting the effectiveness of evidence-based treatments. Previous studies have mostly relied on indirect adherence measures to analyse outcomes based on adherence. The aim of this study was to use LC-MS/MS in urine-a non-invasive, direct and objective measure-to assess non-adherence to cardiometabolic drugs and analyse its association with kidney and cardiovascular outcomes...
April 22, 2024: Diabetologia
https://read.qxmd.com/read/38646849/network-pharmacology-and-molecular-docking-based-strategy-for-predicting-anti-tumour-mechanism-of-linarin
#19
JOURNAL ARTICLE
Jun Wang, Jingjing Cheng
The aim was to explore the anti-tumour mechanism of linarin (LIN) based on network pharmacology and molecular docking. PharmMapper database and GeneCards database were used to screen anti-tumour related targets of LIN. Enrichment analysis of GO and KEGG was conducted to predict the key targets and pathways. At last, LIN was docked with the key targets. ESR1, ESR2, EGFR, AR, TGFBR2, F2, MAPK10, MAPK14, CDK2 and HSP90AA1 were identified as the key targets. The key pathways included pathways in cancer, prostate cancer, pancreatic cancer and breast cancer...
April 22, 2024: Natural Product Research
https://read.qxmd.com/read/38646842/sarcopenia-adiposity-and-large-discordance-between-cystatin-c-and-creatinine-based-estimated-glomerular-filtration-rate-in-patients-with-cancer
#20
JOURNAL ARTICLE
Paul E Hanna, Tianqi Ouyang, Ismail Tahir, Nurit Katz-Agranov, Qiyu Wang, Lea Mantz, Ian Strohbehn, Daiana Moreno, Destiny Harden, James E Dinulos, Duru Cosar, Harish Seethapathy, Justin F Gainor, Sachin J Shah, Shruti Gupta, David E Leaf, Florian J Fintelmann, Meghan E Sise
BACKGROUND: Creatinine-based estimated glomerular filtration rate (eGFRCRE ) may overestimate kidney function in patients with sarcopenia. While cystatin C-based eGFR (eGFRCYS ) is less affected by muscle mass, it may underestimate kidney function in patients with obesity. We sought to evaluate the relationship between body composition defined by computed tomography (CT) scans and discordance between creatinine, eGFRCRE and eGFRCYS in adult patients with cancer. METHODS: This study is a cross-sectional study of consecutive adults with cancer with an abdominal CT scan performed within 90 days of simultaneous eGFRCRE and eGFRCYS measurements between May 2010 and January 2022...
April 22, 2024: Journal of Cachexia, Sarcopenia and Muscle
keyword
keyword
2132
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.